Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 50 % of short-term debt in 2025; threshold 65 %.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2025.
-
Busy address KBO
20 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
NOVADIP BIOSCIENCES from Mont-Saint-Guibert, company number BE0535575602, closed financial year 2025 with a result of € -13.1 million after tax. For that financial year NOVADIP BIOSCIENCES recorded a gross margin of € 1.6 million and equity of € 50 million. Compared with financial year 2024, the result moved from € -2.6 million to € -13.1 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 14, 2026.
€ 50 million
▼ 25% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -13.1 million
▼ 399 % more loss than in 2024
Profit after tax over the fiscal year.
€ 877,863
▲ 141% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -30.5 million.
People and assets in 2025
39.3
▼ 6.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 3.6 million
▼ 9% vs 2024
€ 91,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 127,143
▼ 34% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 10.1 million
▲ € 9.7 million vs 2024
Loans from banks and other lenders, long and short.
€ 2 million
▲ 49% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 708,040
▲ 28% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | - | - | € 2,210,289 | € 1,630,895 | ▼ 26% |
| Profit after taxes | € -2,307,660 | € -1,944,179 | € -2,634,120 | € -13,136,640 | ▼ € 10.5 million |
| Equity | € 65,077,098 | € 66,182,385 | € 66,568,912 | € 49,976,039 | ▼ 25% |
| Total debts | € 7,558,324 | € 14,035,569 | € 24,975,453 | € 35,296,388 | ▲ 41% |
| Cash | € 3,306,157 | € 665,749 | € 364,748 | € 877,863 | ▲ 141% |
| Retained profit | € -12,817,215 | € -14,761,394 | € -17,395,514 | € -30,532,154 | ▼ € 13.1 million |
| Bank debt | € 0 | € 149,546 | € 452,644 | € 10,140,866 | ▲ € 9.7 million |
| Balance sheet total | € 72,672,839 | € 80,255,372 | € 91,544,365 | € 85,272,427 | ▼ 7% |
| Employees (FTE) | 37.8 | 39.5 | 45.6 | 39.3 | ▼ 6.3 |
Key figures of NOVADIP BIOSCIENCES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to NOVADIP BIOSCIENCES?
What happened at NOVADIP BIOSCIENCES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Drew Trivisonno stepped down as director. NBB
- THERACELL CONSULTING stepped down as director. NBB
- VIVES Partners stepped down as director. NBB
- SPARAXIS stepped down as director. NBB
- Jean-Pierre BIZET stepped down as director. NBB
- AXXIS V&C SRL stepped down as director. NBB
- Patrick VAN BENEDEN stepped down as director. NBB
- Eric PÂQUES stepped down as director. NBB
In short
From € 2.3 million loss in 2022 to € 13.1 million loss in 2025.
Paid € 6 in corporate taxes since 2022.
On average € 41,500 of value added per employee in 2025.
A new publication or filing at NOVADIP BIOSCIENCES? We notify you, reason included.
Follow NOVADIP BIOSCIENCESDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Fund+, VIVES II - Louvain Technology Fund, SOCIETE D'INVESTISSEMENT ET DE FINANCEMENT DU BRABANT WALLON, SOPARTEC, Theracell Consulting, INVESTSUD TECH comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
NOVADIP BIOSCIENCESBehind NOVADIP BIOSCIENCES is Da Liu. The shares are held by Fund+ (20.1%), VIVES II - Louvain Technology Fund (12.5%), SOCIETE D'INVESTISSEMENT ET DE FINANCEMENT DU BRABANT WALLON (2.1%), SOPARTEC (1.7%), Theracell Consulting (1.5%) and INVESTSUD TECH (1.5%).
Directors
According to the 2025 annual accounts
Da Liu
Director
Drew Trivisonno
Director
since 2024 · until 2027
Managing director · represented by Denis DUFRANE
since 2021 · until 2027
Director · represented by Philippe DURIEUX
since 2021 · until 2027
Director · represented by Christine Franssen
Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International, Ateliers Pierre Cerfontaine, Floridienne, Fonderies J. Marichal Ketin et Cie, JUNGLING, MEBF +223 more
since 2021 · until 2027
Jean-Pierre BIZET
Director
since 2021 · until 2027
since 2021 · until 2027
Patrick VAN BENEDEN
Director
since 2023 · until 2027
Eric PÂQUES
Director
since 2021 · until 2027
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Granbonpré 11
1435 Mont-Saint-Guibert
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
All companies at this address →DE SMET AGRO
€ 8.7 million revenue · 2025
DE SMET S.A. - ENGINEERS & CONTRACTORS same network
€ 31.8 million revenue · 2025
CEDRIC CLAERHOUDT
€ 937,969 gross margin · 2024
Tools4Patient same network
€ -431,027 gross margin · 2025
The Akkermansia Company same network
€ -1.5 million gross margin · 2024
+15 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0535.575.602
- VAT number
- BE 0535.575.602
- Registered office
- Rue Granbonpré 11, 1435 Mont-Saint-Guibert
- Names & denominations
- NOVADIP BIOSCIENCES
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 31 May 2013
- Peppol
- Active · Active since 27 Nov 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied